175 related articles for article (PubMed ID: 36706720)
1. Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas.
Ando K; Natsumeda M; Kawamura M; Shirakawa K; Okada M; Tsukamoto Y; Eda T; Watanabe J; Saito S; Takahashi H; Kakita A; Oishi M; Fujii Y
Thromb Res; 2023 Mar; 223():36-43. PubMed ID: 36706720
[TBL] [Abstract][Full Text] [Related]
2. Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
Watanabe J; Natsumeda M; Okada M; Kanemaru Y; Tsukamoto Y; Oishi M; Kakita A; Fujii Y
World Neurosurg; 2019 Aug; 128():e982-e988. PubMed ID: 31100523
[TBL] [Abstract][Full Text] [Related]
3. Early recognition of sepsis-induced coagulopathy using the C2PAC index: a ratio of soluble type C lectin-like receptor 2 (sCLEC-2) level and platelet count.
Ishikura H; Irie Y; Kawamura M; Hoshino K; Nakamura Y; Mizunuma M; Maruyama J; Nakashio M; Suzuki-Inoue K; Kitamura T
Platelets; 2022 Aug; 33(6):935-944. PubMed ID: 35073814
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis.
Low SK; Anjum Z; Mahmoud A; Joshi U; Kouides P
Thromb Res; 2022 Nov; 219():14-21. PubMed ID: 36088710
[TBL] [Abstract][Full Text] [Related]
5. Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
Diaz M; Jo J; Smolkin M; Ratcliffe SJ; Schiff D
Neurology; 2021 Feb; 96(7):e1063-e1069. PubMed ID: 33361259
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
7. Determining venous thromboembolism risk in patients with adult-type diffuse glioma.
Burdett KB; Unruh D; Drumm M; Steffens A; Lamano J; Judkins J; Schwartz M; Javier R; Amidei C; Lipp ES; Peters KB; Lai A; Eldred BSC; Heimberger AB; McCortney K; Scholtens DM; Horbinski C
Blood; 2023 Mar; 141(11):1322-1336. PubMed ID: 36399711
[TBL] [Abstract][Full Text] [Related]
8. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
Mir Seyed Nazari P; Riedl J; Preusser M; Posch F; Thaler J; Marosi C; Birner P; Ricken G; Hainfellner JA; Pabinger I; Ay C
J Thromb Haemost; 2018 Jun; 16(6):1121-1127. PubMed ID: 29676036
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells.
Costa B; Eisemann T; Strelau J; Spaan I; Korshunov A; Liu HK; Bugert P; Angel P; Peterziel H
Blood Adv; 2019 Apr; 3(7):1092-1102. PubMed ID: 30948364
[TBL] [Abstract][Full Text] [Related]
10. Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
Osada Y; Saito R; Miyata S; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
Brain Tumor Pathol; 2021 Jul; 38(3):218-227. PubMed ID: 34269949
[TBL] [Abstract][Full Text] [Related]
11. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
[TBL] [Abstract][Full Text] [Related]
12. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
[TBL] [Abstract][Full Text] [Related]
13. IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
Mandel JJ; Youssef M; Yust-Katz S; Patel AJ; Jalali A; Li Z; Wu J; Ludmir EB; de Groot JF
J Neurol Sci; 2021 Aug; 427():117538. PubMed ID: 34146775
[TBL] [Abstract][Full Text] [Related]
14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
15. A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.
Wirthschaft P; Bode J; Simon AEM; Hoffmann E; van Laack R; Krüwel T; Dietrich F; Bucher D; Hahn A; Sahm F; Breckwoldt MO; Kurz FT; Hielscher T; Fischer B; Dross N; Ruiz de Almodovar C; von Deimling A; Herold-Mende C; Plass C; Boulant S; Wiestler B; Reifenberger G; Lichter P; Wick W; Tews B
Int J Cancer; 2018 Sep; 143(5):1176-1187. PubMed ID: 29582423
[TBL] [Abstract][Full Text] [Related]
16. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
[TBL] [Abstract][Full Text] [Related]
17. C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls.
Etemad M; Christodoulou F; Uhlig S; Hassel JC; Schrotz-King P; Brenner H; Ulrich CM; Bieback K; Klüter H; Bugert P
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067218
[TBL] [Abstract][Full Text] [Related]
18. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
